CN101607070A - A kind of pharmaceutical composition that is used for the treatment of cardiovascular and cerebrovascular disease - Google Patents
A kind of pharmaceutical composition that is used for the treatment of cardiovascular and cerebrovascular disease Download PDFInfo
- Publication number
- CN101607070A CN101607070A CNA2009100672741A CN200910067274A CN101607070A CN 101607070 A CN101607070 A CN 101607070A CN A2009100672741 A CNA2009100672741 A CN A2009100672741A CN 200910067274 A CN200910067274 A CN 200910067274A CN 101607070 A CN101607070 A CN 101607070A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- quintessence oils
- ethanol extract
- total
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of pharmaceutical composition that is used for the treatment of cardiovascular and cerebrovascular disease, belong to a kind of Chinese medicine composition.Include active substance: 5～15 parts of Caulis Spatholobi total flavones by following weight fraction ratio, 3～10 parts of Radix Paeoniae Rubra total glycosidess, 4～15 parts of Radix Curcumae sesquiterpenes, 6～15 parts of Pericarpium Citri Reticulatae quintessence oils, 5～15 parts of Fructus Lycii ethanol extract, Radix Ophiopogonis, water extract was 6～20 parts, 1～5 part of amygdalin, 3～10 parts of Flos Carthami water extracts, 5～15 parts of Radix Notoginseng total arasaponinss, 2～10 parts of Radix Aucklandiae quintessence oils, 15～30 parts of Rhizoma Polygonati ethanol extract, 0.5～5 part of Borneolum Syntheticum, 6～20 parts of Radix Salviae Miltiorrhizae ethanol extract, 3～15 parts of Lignum Dalbergiae Odoriferae quintessence oils, 2～10 parts of Rhizoma Chuanxiong ferulic acids, 4～10 parts of Rhizoma Acori Graminei quintessence oils, 2～10 parts of Radix Ginseng total saponinss.Be used for the treatment of the angina pectoris that coronary atherosclerosis causes, sensation of oppression over the chest with shortness of breath, deficiency of heart-QI, blood stasis disease such as have a pain.
Description
Technical field
The invention belongs to a kind of Chinese medicine composition, refer in particular to and be used for the treatment of the angina pectoris that coronary atherosclerosis causes, sensation of oppression over the chest with shortness of breath, deficiency of heart-QI, blood stasis is had a pain.
Background technology
Coronary heart disease is a kind of organic by coronary artery, myocardial ischemia-anoxemia, angina pectoris or the myocardial necrosis that atherosclerosis or dynamic property vasospasm, stenosis or occlusion cause, the heart disease of myocardial infarction, be a kind of modal heart disease, be meant the myocardial dysfunction and or the organic disease that cause because of coronary stricture, blood supply insufficiency.Cerebral arteriosclerosis is the part of GAS, also is the especially main pathogenesis basis of cerebral ischemia attack of acute brain blood circulation simultaneously.High blood viscosity is exactly the excessive thickness of blood, be owing to erythrocyte aggregation bunchiness in the blood, lose due gap and distance, perhaps the crooked deformability of erythrocyte by small blood capillary the time descends in the blood, the viscosity of blood is increased, circulation resistance increases, due to microcirculation blood flow is not smooth.The traditional Chinese medical science thinks that obstruction of qi in the chest and cardialgia belongs to the deficiency in origin and excess in superficiality card more, and treatment is many based on activating blood circulation to dissipate blood stasis, and assistant is regulated the flow of vital energy and promoted blood circulation with the QI invigorating warming YANG.
At present the more of chemicals used in the treatment of above-mentioned cardiovascular and cerebrovascular disease but because of problems such as end-of-dose failure and toxic and side effects, be difficult to treatment, present above-mentioned treatment of conditions still has no side effect little or has no side effect, can take for a long time, reduce the desirable medicine of recurrence, the desirable medicine of above-mentioned treatment for diseases still remains to be developed.Because cardiovascular and cerebrovascular disease serious harm public health, in China's disease cause of death, cerebrovascular disease has surpassed cancer and has occupied first, and the cardiovascular diseases occupies second.Economically developed countries and regions such as American-European-Japanese, public's disease cause of death central vessel is sick to occupy first, and cerebrovascular occupies second, needs curative effect rapid for this reason, and effect is certain, has no side effect, the medicine that can prevent to recur and can take for a long time.
Summary of the invention
The invention provides a kind of pharmaceutical composition that is used for the treatment of cardiovascular and cerebrovascular disease, be used for the treatment of the angina pectoris that coronary atherosclerosis causes, sensation of oppression over the chest with shortness of breath, deficiency of heart-QI, blood stasis is had a pain.The technical scheme that the present invention takes is: include the active substance by following weight fraction ratio:
5～15 parts of Caulis Spatholobi total flavones, 3～10 parts of Radix Paeoniae Rubra total glycosidess, 4～15 parts of Radix Curcumae sesquiterpenes, 6～15 parts of Pericarpium Citri Reticulatae quintessence oils, 5～15 parts of Fructus Lycii ethanol extract, Radix Ophiopogonis, water extract was 6～20 parts, 1～5 part of amygdalin, 3～10 parts of Flos Carthami water extracts, 5～15 parts of Radix Notoginseng total arasaponinss, 2～10 parts of Radix Aucklandiae quintessence oils, 15～30 parts of Rhizoma Polygonati ethanol extract, 0.5～5 part of Borneolum Syntheticum, 6～20 parts of Radix Salviae Miltiorrhizae ethanol extract, 3～15 parts of Lignum Dalbergiae Odoriferae quintessence oils, 2～10 parts of Rhizoma Chuanxiong ferulic acids, 4～10 parts of Rhizoma Acori Graminei quintessence oils, 2～10 parts of Radix Ginseng total saponinss.
Above-mentioned various extracts among the present invention can be by extracting method acquisition arbitrarily in the prior art.Be preferably:
The Caulis Spatholobi total flavones: it is an amount of to take by weighing raw material, with 50%-90% alcohol reflux 1-3 hour, adds 6-16 times of ethanol at every turn and decocts 0.5-3 hour, filters, and merging filtrate concentrates.
Radix Paeoniae Rubra total glycosides: it is an amount of to take by weighing raw material, adds 5-14 times of ethanol and decocts 0.5-3 hour with 50%-90% alcohol reflux 1-3 time is each, filter, and merging filtrate, concentrated.
The Radix Curcumae sesquiterpene: it is an amount of to take by weighing raw material, and water decocts 1-3 time and adds 5-15 times of decocting and boil and filtered merging filtrate in 0.5-3 hour at every turn, and is concentrated.
The Pericarpium Citri Reticulatae quintessence oil: it is an amount of to take by weighing raw material, and with distilled water reflux, extract, 1-3 time, add 7-15 times of distilled water at every turn and boil filtration in 1-3 hour, merging filtrate, concentrated.
The Fructus Lycii ethanol extract: it is an amount of to take by weighing raw material, adds 5-14 times of ethanol and decocts 0.5-3 hour with 50%-90% alcohol reflux 1-3 time is each, filter, and merging filtrate, concentrated.
Radix Ophiopogonis water extract: it is an amount of to take by weighing raw material, and water decocts 1-3 time and adds 6-17 times of decocting and boil and filtered merging filtrate in 0.5-3 hour at every turn, and is concentrated.
Amygdalin: it is an amount of to take by weighing raw material, and water decocts 1-3 time and adds 5-15 times of decocting and boil and filtered merging filtrate in 0.5-3 hour at every turn, and is concentrated.
The Flos Carthami water extract: it is an amount of to take by weighing raw material, and water decocts 1-3 time and adds 5-17 times of decocting and boil and filtered merging filtrate in 0.5-3 hour at every turn, and is concentrated.
Radix Notoginseng total arasaponins: it is an amount of to take by weighing raw material, adds 5-14 times of ethanol and decocts 0.5-3 hour with 50%-90% alcohol reflux 1-3 time is each, filter, and merging filtrate, concentrated.
Radix Aucklandiae quintessence oil: it is an amount of to take by weighing raw material, and with distilled water reflux, extract, 1-3 time, add 7-15 times of distilled water at every turn and boil filtration in 1-3 hour, merging filtrate, concentrated.
The Rhizoma Polygonati ethanol extract: it is an amount of to take by weighing raw material, adds 5-16 times of ethanol and decocts 0.5-3 hour with 50%-90% alcohol reflux 1-3 time is each, filter, and merging filtrate, concentrated.
The Radix Salviae Miltiorrhizae ethanol extract: it is an amount of to take by weighing raw material, adds 5-16 times of ethanol and decocts 0.5-3 hour with 50%-90% alcohol reflux 1-3 time is each, filter, and merging filtrate, concentrated.
The Lignum Dalbergiae Odoriferae quintessence oil: it is an amount of to take by weighing raw material, and with distilled water reflux, extract, 1-3 time, add 7-15 times of distilled water at every turn and boil filtration in 1-3 hour, merging filtrate, concentrated.
The Rhizoma Chuanxiong ferulic acid: it is an amount of to take by weighing raw material, adds 6-18 times of ethanol and decocts 0.5-3 hour with 50%-90% alcohol reflux 1-3 time is each, filter, and merging filtrate, concentrated.
The Rhizoma Acori Graminei quintessence oil: it is an amount of to take by weighing raw material, and with distilled water reflux, extract, 1-3 time, add 7-15 times of distilled water at every turn and boil filtration in 1-3 hour, merging filtrate, concentrated.
Radix Ginseng total saponins: it is an amount of to take by weighing raw material, adds 6-15 times of ethanol and decocts 0.5-3 hour with 50%-90% alcohol reflux 1-3 time is each, filter, and merging filtrate, concentrated.
The present invention can be mixed with medicament with one or more pharmaceutically acceptable carriers or adjuvant.
Above-mentioned pharmaceutically acceptable carrier is meant the pharmaceutical carrier or the adjuvant of pharmaceutical field routine, for example: diluent, excipient and water etc., filler such as starch, dextrin, sucrose, mannitol, lactose, microcrystalline Cellulose etc.; Binding agent such as cellulose derivative, alginate, gelatin and polyvinylpyrrolidone; Wetting agent such as glycerol: disintegrating agent such as methyl starch sodium, hyprolose, cross-linked carboxymethyl cellulose, agar, calcium carbonate and sodium bicarbonate; Absorption enhancer such as quaternary ammonium compound; Surfactant such as hexadecanol, Tween 80, sodium lauryl sulphate; Alms bowl such as Kaolin and soap clay are carried in absorption; Lubricant such as Pulvis Talci, calcium stearate and magnesium, micropowder silica gel and Polyethylene Glycol etc.In medicament, can also contain other adjuvant such as flavouring agent, sweeting agent etc. in addition.
The medicament that the present invention makes can be applied to the patient by the mode of oral, rectum or parenteral.Be used for when oral, can be made into conventional solid preparation such as tablet, capsule, powder, granule etc., make other liquid preparation of liquid preparation such as water or oil-suspending agent such as syrup, mixture, elixir etc.; When being used for parenteral, can be made into solution, powder pin, water or the oiliness suspending agent etc. of injection.The preferred form of the present invention is oral liquid, tablet, coated tablet, capsule, granule.
The present invention is used for the treatment of the angina pectoris that coronary atherosclerosis causes, sensation of oppression over the chest with shortness of breath, deficiency of heart-QI, blood stasis disease such as have a pain.The amount of application of the present invention and medicament thereof can be according to variations such as the type of route of administration, patient age, body weight, the disease of being treated and the orders of severity, 5 of oral doses one time, 3-4 time on the one.
The specific embodiment
Further verify the present invention below by Pharmacodynamic test of active extract.
1 experiment material
1.1 animal health Wistar rat, body weight 250-300g, healthy Kunming mouse, body weight 18-20g provides by laboratory animal room of Henan Privincial Medicaments Inspection Inst., No. the 050504th, the moving word of quality certification Henan doctor.
1.2 medicine and reagent tablet for promoting coronary circulation provide lot number 050527 by JiLin ZiXin Pharmacy Co., Ltd, every gram is equivalent to contain crude drug 2.14g:; FUFANG DANSHEN PIAN, White Cloud Mountain, Guangzhou pharmaceutical factory produces, lot number 000207608; Aspirin tablet, Zhengzhou City chemical pharmaceutical factory produces, and lot number 040420, above medicine face with preceding prepares desired concn with 0.5%CMCNa.Sodium carboxymethyl cellulose (CMCNa), Shanghai chemical reagent purchasing and supply station is produced, lot number 760419; Creatine kinase (CK-NAC) test kit, Beijing Zhongsheng Biological Engineering High Technology Company, lot number 050201; Lactic acid dehydrogenase (LDH-L) test kit, Beijing Zhongsheng Biological Engineering High Technology Company, lot number 050401.
1.3 instrument CL-770 biochemistry analyzer, day island proper Tianjin company.
2 methods and result
2.1 influence to the rat experiment myocardial inyaretion
Get female rats, random packet, gastric infusion, every day 1 time, high, medium and low dosage is equivalent to 10 times, 8 times, 5 times of clinical consumption approximately, continuously 7d, 60min after the last administration, etherization is rat fixedly, under artificial respirator, breast is opened in operation fast, expose heart, with the ligation of anterior descending coronary root, the blocking-up coronary blood flow, rapidly heart is put back to the thoracic cavity, sew up thoracic wall.Behind the 24h, put to death rat, get blood system serum, measure CK and LDH content in the serum, the results are shown in Table 1.Simultaneously, it is dirty to core, and cleans surplus blood, removes atrium and blood vessel, thinly slice after ventricle weighed, put in the 0.5% nitro blue tetrazolium solution, hatch among the 15min for 37 ℃, cut off painted cardiac muscle (infarcted myocardium is not painted), infarcted myocardium is weighed, by the following formula infarct size
Table 1 tablet for promoting coronary circulation to rat myocardium block after in the serum CK and LDH influence (x ± s, n=10)
Annotate: compare with model control group,
★P＜0.05,
★ ★P＜0.01.
Table 2 tablet for promoting coronary circulation to the influence of rat myocardium block area (x ± s, n=10)
Annotate: compare with model control group,
★P＜0.05,
★ ★P＜0.01.
Table 1 table 2 is the result show, the high, medium and low dosage group of tablet for promoting coronary circulation all can obviously reduce behind the coronary ligation CK and LDH content in the rat blood serum, reduces the area of myocardial infarction behind the coronary ligation, and the myocardial damage degree is alleviated.With model control group comparing difference significance, there is not significance (p＞0.05) with FUFANG DANSHEN PIAN group comparing difference.
2.2 to the thrombotic influence of rat vein
Get male rat, random packet, gastric infusion, every day 1 time, continuous 7d, 30min after the last administration, the anesthesia of 0.5% urethane is rat fixedly, separate a left side (right side) side common carotid artery and the right side (left side) jugular vein, get the polyethylene tube that there is the 5cm silk thread in the stage casing and is full of heparin sodium aqua (50u/ml), carry out arteriovenous and put up a bridge, middle Herba Clinopodii behind the open blood flow 15min, take by weighing silk thread, it is wet weight of thrombus that gross weight deducts silk thread weight.The results are shown in Table 3
The influence that table 3 tablet for promoting coronary circulation forms rat suppository (x ± s, n=10)
Annotate: compare with the normal control group,
★P＜0.05,
★ ★P＜0.01.
Table 3 result shows that the high, medium and low dosage group of tablet for promoting coronary circulation all can obviously suppress thrombosis, reduces the thrombosis rate.Compare with the normal control group, difference has significance, and certain dose-effect relationship is arranged; With FUFANG DANSHEN PIAN group comparing difference nonsignificance (p＞0.05).
2.3 analgesic experiment
2,3.1 writhing method is got mice, male and female half and half, random packet, gastric infusion, every day 1 time, high and low dose is equivalent to 18 times, 13 times, 9 times of clinical consumption approximately, continuously 7d, 30min after the last administration, lumbar injection 0.7% acetum 10ml/kg, each Mus occurs in the observed and recorded 20min turns round the body number of times, and calculates the analgesia percentage rate that is subjected to the reagent thing.The results are shown in Table 4.
Table 4 tablet for promoting coronary circulation Dichlorodiphenyl Acetate cause mouse writhing inhibitory action (x ± s, n=10)
Annotate: compare with the normal control group,
★P＜0.05,
★ ★P＜0.01.
2.3.2 hot plate method is got the female mice that pain threshold (55 ℃ of hot plates) is no more than 30s, random packet, gastric infusion, every day 1 time, continuous 7d, 60min after the last administration puts mice respectively on 55 ℃ of hot plates, write down it and lick the metapedes time, survey continuously 2 times, average.The results are shown in Table 5
Table 5 tablet for promoting coronary circulation to hot plate cause mice pain inhibitory action (x ± s, n=10)
Annotate: compare with the normal control group,
★P＜0.05,
★ ★P＜0.01.
Experimental result shows that the mice pain that tablet for promoting coronary circulation high, medium and low dosage group Dichlorodiphenyl Acetate and thermostimulation cause all has significant inhibitory effect.
2.4 mice is got in the anoxia enduring experiment, male and female half and half, and random packet, gastric infusion, every day is inferior, continuous 7d, 60min after the last administration is incorporated with mice respectively in the wide mouthed bottle of sodica calx, and is airtight, the record anoxia in mice death time.The results are shown in Table 6.
Table 6 tablet for promoting coronary circulation to the influence of mice hypoxia endurance time (x ± s, n=10)
Annotate: compare with the normal control group,
★P＜0.05,
★ ★P＜0.01.
Experimental result shows that the high, medium and low dosage group of tablet for promoting coronary circulation can significantly improve the hypoxia endurance time of mice, prolongs it in the normobaric hypoxia following time-to-live of condition; With normal control group comparing difference significance, with FUFANG DANSHEN PIAN comparing difference nonsignificance (P＞0.05).
Above-mentioned each experimental verification blood circulation and channel invigorating of the present invention, the effect of heart tonifying paroxysmal pain is for clinical application provides the pharmacology foundation
The preparation of embodiment 1 capsule of the present invention
Caulis Spatholobi total flavones 50g, Radix Paeoniae Rubra total glycosides 30g, Radix Curcumae sesquiterpene 40g, Pericarpium Citri Reticulatae quintessence oil 60g, Fructus Lycii ethanol extract 50g, Radix Ophiopogonis water extract 60g, amygdalin 10g, Flos Carthami water extract 30g, Radix Notoginseng total arasaponins 50g, Radix Aucklandiae quintessence oil 20g, Rhizoma Polygonati ethanol extract 150g, Borneolum Syntheticum 5g, Radix Salviae Miltiorrhizae ethanol extract 60g, Lignum Dalbergiae Odoriferae quintessence oil 30g, Rhizoma Chuanxiong ferulic acid 20g, Rhizoma Acori Graminei quintessence oil 40g, Radix Ginseng total saponins 20g.
The conventional adjuvant that adds the preparation capsule is granulated, and is encapsulated.
Above-mentioned various extracts among the present invention can be by extracting method acquisition arbitrarily in the prior art.Be preferably:
The Caulis Spatholobi total flavones: it is an amount of to take by weighing raw material, with 50%-90% alcohol reflux 1-3 hour, adds 6-16 times of ethanol at every turn and decocts 0.5-3 hour, filters, and merging filtrate concentrates.
Radix Paeoniae Rubra total glycosides: it is an amount of to take by weighing raw material, adds 5-14 times of ethanol and decocts 0.5-3 hour with 50%-90% alcohol reflux 1-3 time is each, filter, and merging filtrate, concentrated.
The Radix Curcumae sesquiterpene: it is an amount of to take by weighing raw material, and water decocts 1-3 time and adds 5-15 times of decocting and boil and filtered merging filtrate in 0.5-3 hour at every turn, and is concentrated.
The Pericarpium Citri Reticulatae quintessence oil: it is an amount of to take by weighing raw material, and with distilled water reflux, extract, 1-3 time, add 7-15 times of distilled water at every turn and boil filtration in 1-3 hour, merging filtrate, concentrated.
The Fructus Lycii ethanol extract: it is an amount of to take by weighing raw material, adds 5-14 times of ethanol and decocts 0.5-3 hour with 50%-90% alcohol reflux 1-3 time is each, filter, and merging filtrate, concentrated.
Radix Ophiopogonis water extract: it is an amount of to take by weighing raw material, and water decocts 1-3 time and adds 6-17 times of decocting and boil and filtered merging filtrate in 0.5-3 hour at every turn, and is concentrated.
Amygdalin: it is an amount of to take by weighing raw material, and water decocts 1-3 time and adds 5-15 times of decocting and boil and filtered merging filtrate in 0.5-3 hour at every turn, and is concentrated.
The Flos Carthami water extract: it is an amount of to take by weighing raw material, and water decocts 1-3 time and adds 5-17 times of decocting and boil and filtered merging filtrate in 0.5-3 hour at every turn, and is concentrated.
Radix Notoginseng total arasaponins: it is an amount of to take by weighing raw material, adds 5-14 times of ethanol and decocts 0.5-3 hour with 50%-90% alcohol reflux 1-3 time is each, filter, and merging filtrate, concentrated.
Radix Aucklandiae quintessence oil: it is an amount of to take by weighing raw material, and with distilled water reflux, extract, 1-3 time, add 7-15 times of distilled water at every turn and boil filtration in 1-3 hour, merging filtrate, concentrated.
The Rhizoma Polygonati ethanol extract: it is an amount of to take by weighing raw material, adds 5-16 times of ethanol and decocts 0.5-3 hour with 50%-90% alcohol reflux 1-3 time is each, filter, and merging filtrate, concentrated.
The Radix Salviae Miltiorrhizae ethanol extract: it is an amount of to take by weighing raw material, adds 5-16 times of ethanol and decocts 0.5-3 hour with 50%-90% alcohol reflux 1-3 time is each, filter, and merging filtrate, concentrated.
The Lignum Dalbergiae Odoriferae quintessence oil: it is an amount of to take by weighing raw material, and with distilled water reflux, extract, 1-3 time, add 7-15 times of distilled water at every turn and boil filtration in 1-3 hour, merging filtrate, concentrated.
The Rhizoma Chuanxiong ferulic acid: it is an amount of to take by weighing raw material, adds 6-18 times of ethanol and decocts 0.5-3 hour with 50%-90% alcohol reflux 1-3 time is each, filter, and merging filtrate, concentrated.
The Rhizoma Acori Graminei quintessence oil: it is an amount of to take by weighing raw material, and with distilled water reflux, extract, 1-3 time, add 7-15 times of distilled water at every turn and boil filtration in 1-3 hour, merging filtrate, concentrated.
Radix Ginseng total saponins: it is an amount of to take by weighing raw material, adds 6-15 times of ethanol and decocts 0.5-3 hour with 50%-90% alcohol reflux 1-3 time is each, filter, and merging filtrate, concentrated.
The preparation of embodiment 2 tablets of the present invention
Caulis Spatholobi total flavones 100g, Radix Paeoniae Rubra total glycosides 65g, Radix Curcumae sesquiterpene 95g, Pericarpium Citri Reticulatae quintessence oil 105g, Fructus Lycii ethanol extract 100g, Radix Ophiopogonis water extract 130g, amygdalin 30g, Flos Carthami water extract 65g, Radix Notoginseng total arasaponins 100g, Radix Aucklandiae quintessence oil 60g, Rhizoma Polygonati ethanol extract 225g, Borneolum Syntheticum 27.5g, Radix Salviae Miltiorrhizae ethanol extract 130g, Lignum Dalbergiae Odoriferae quintessence oil 90g, Rhizoma Chuanxiong ferulic acid 60g, Rhizoma Acori Graminei quintessence oil 70g, Radix Ginseng total saponins 60g.
Add the conventional adjuvant 4487.5g of preparation tablet, make 20000, every heavy 0.3g.
The preparation of embodiment 3 granules of the present invention
Caulis Spatholobi total flavones 150g, Radix Paeoniae Rubra total glycosides 100g, Radix Curcumae sesquiterpene 150g, Pericarpium Citri Reticulatae quintessence oil 150g, Fructus Lycii ethanol extract 150g, Radix Ophiopogonis water extract 200g, amygdalin 50g, Flos Carthami water extract 100g, Radix Notoginseng total arasaponins 150g, Radix Aucklandiae quintessence oil 100g, Rhizoma Polygonati ethanol extract 300g, Borneolum Syntheticum 50g, Radix Salviae Miltiorrhizae ethanol extract 200g, Lignum Dalbergiae Odoriferae quintessence oil 150g, Rhizoma Chuanxiong ferulic acid 100g, Rhizoma Acori Graminei quintessence oil 100g, Radix Ginseng total saponins 100g.
Add the conventional adjuvant of preparation tablet, make granule.
Claims (2)
1, a kind of pharmaceutical composition that is used for the treatment of cardiovascular and cerebrovascular disease, it is characterized in that including active substance: 5～15 parts of Caulis Spatholobi total flavones by following weight fraction ratio, 3～10 parts of Radix Paeoniae Rubra total glycosidess, 4～15 parts of Radix Curcumae sesquiterpenes, 6～15 parts of Pericarpium Citri Reticulatae quintessence oils, 5～15 parts of Fructus Lycii ethanol extract, Radix Ophiopogonis, water extract was 6～20 parts, 1～5 part of amygdalin, 3～10 parts of Flos Carthami water extracts, 5～15 parts of Radix Notoginseng total arasaponinss, 2～10 parts of Radix Aucklandiae quintessence oils, 15～30 parts of Rhizoma Polygonati ethanol extract, 0.5～5 part of Borneolum Syntheticum, 6～20 parts of Radix Salviae Miltiorrhizae ethanol extract, 3～15 parts of Lignum Dalbergiae Odoriferae quintessence oils, 2～10 parts of Rhizoma Chuanxiong ferulic acids, 4～10 parts of Rhizoma Acori Graminei quintessence oils, 2～10 parts of Radix Ginseng total saponinss.
2, the pharmaceutical composition that is used for the treatment of cardiovascular and cerebrovascular disease according to claim 1, it is characterized in that including active substance: 10 parts of Caulis Spatholobi total flavones by following weight fraction ratio, 6.5 parts of Radix Paeoniae Rubra total glycosidess, 9.5 parts of Radix Curcumae sesquiterpenes, 10.5 parts of Pericarpium Citri Reticulatae quintessence oils, 10 parts of Fructus Lycii ethanol extract, Radix Ophiopogonis, water extract was 13 parts, 3 parts of amygdalins, 6.5 parts of Flos Carthami water extracts, 10 parts of Radix Notoginseng total arasaponinss, 6 parts of Radix Aucklandiae quintessence oils, 22.5 parts of Rhizoma Polygonati ethanol extract, 2.75 parts of Borneolum Syntheticums, 1.3 parts of Radix Salviae Miltiorrhizae ethanol extract, 9 parts of Lignum Dalbergiae Odoriferae quintessence oils, 6 parts of Rhizoma Chuanxiong ferulic acids, 7 parts of Rhizoma Acori Graminei quintessence oils, 6 parts of Radix Ginseng total saponinss.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100672741A CN101607070B (en) | 2009-07-15 | 2009-07-15 | Pharmaceutical composition for treating heart cerebrovascular disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100672741A CN101607070B (en) | 2009-07-15 | 2009-07-15 | Pharmaceutical composition for treating heart cerebrovascular disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101607070A true CN101607070A (en) | 2009-12-23 |
| CN101607070B CN101607070B (en) | 2012-01-04 |
Family
ID=41481083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100672741A Active CN101607070B (en) | 2009-07-15 | 2009-07-15 | Pharmaceutical composition for treating heart cerebrovascular disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101607070B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106726494A (en) * | 2016-12-22 | 2017-05-31 | 云南贝洋生物科技有限公司 | A kind of moxaburner |
-
2009
- 2009-07-15 CN CN2009100672741A patent/CN101607070B/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106726494A (en) * | 2016-12-22 | 2017-05-31 | 云南贝洋生物科技有限公司 | A kind of moxaburner |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101607070B (en) | 2012-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102908583B (en) | Traditional Chinese medicine composition for treating chest stuffiness and pains as well as preparation method, quality detection method and application of composition | |
| CN101002906A (en) | Compounding traditional Chinese medicine, and its use | |
| CN102772748B (en) | Traditional Chinese medicine preparation for treating liver-depression qi-stagnation type viral myocarditis and preparation method thereof | |
| CN102139084A (en) | Chinese medicinal composition for treating fatty liver and preparation method and application thereof | |
| CN104825788B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating transient ischemic attack | |
| CN108186877A (en) | For the Chinese medicine composition of syndrome of blood stasis due to qi deficiency myocardial infarction secondary prevention | |
| CN101380372A (en) | Pharmaceutical composition for treating cervical vertebra disease and its preparation method | |
| CN101099753A (en) | Preparation method and application for general saponin of cortex ilecis rotundae | |
| CN103142844A (en) | Pharmaceutical composition for treating diabetic nephropathy | |
| CN101607070B (en) | Pharmaceutical composition for treating heart cerebrovascular disease | |
| CN101732585A (en) | Medicinal composition for treating migraine, preparation method and application thereof | |
| CN101693059B (en) | Preparation method of rose polyphenol and application thereof in gynaecology and obstetrics | |
| CN103735755A (en) | Traditional Chinese medicinal composition for treating hypertension and preparation method thereof | |
| CN103385931A (en) | Blood-sugar-lowering medicine composition | |
| CN105833055A (en) | Traditional Chinese medicine composition for treating hypertension, hyperlipidemia and hyperglycemia and preparing method and application thereof | |
| CN101129431A (en) | Traditional Chinese medicine composition for preventing and controlling cardiovascular disease and relative disease, method of preparing the same and application of the same | |
| CN105106634A (en) | Traditional Chinese medicine preparation for treating acute appendicitis and application thereof | |
| CN104001026A (en) | Medicine for treating myocardial ischemia | |
| CN104000871A (en) | Drug for treating myocardial ischemia | |
| CN104873909B (en) | The herbal composite for treating asymptomatic non-metastatic castration-resistant prostate cancer | |
| CN113476526B (en) | A Chinese medicinal composition for treating atrial fibrillation, and its preparation method | |
| CN103142781B (en) | Chinese medicine composition and preparation thereof for treating chronic heart failure | |
| CN115177691B (en) | Traditional Chinese medicine composition for treating ventricular premature beat and application thereof | |
| CN103127413B (en) | Pharmaceutical preparation for treating coronary diseases | |
| CN106620070A (en) | Medicinal composition for treating osteoarthropathy and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicine composition for treating cardiac and cerebral vascular diseases and its prepn process Effective date of registration: 20190318 Granted publication date: 20120104 Pledgee: Jilin rural commercial bank and Limited by Share Ltd Pledgor: Jilin Zixin Pharmaceutical Co., Ltd. Registration number: 2019220000006 |
|
| PP01 | Preservation of patent right | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20210929 Granted publication date: 20120104 |